euticals. Inc., Ophthotech Corp. Portola Pharmaceuticals Inc, Relypsa. Inc.. Synageva Biopharma Corp. Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis, Inc.. In the next 3 months. Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Akebia Therapeu

euticals. Inc., Ophthotech Corp, Portola Pharmaceuticals Inc, Relypsa. Inc.. Synageva Biopharma Corp. Theravance Inc, Ultragenyx Pharmaceutical Inc, Versartis, Inc.. In the next 3 months. Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Akebia Therapeu

ma (NLV-II, NASDAQ: ARRY, oncology, exited at 2.25x), Chimerix (NLV-IL, private initially, now public on NASDAQ: CMRX, novel anti-viral therapy), and Versartis (NLV-II, private, novel, long-acting human growth hormone). e Novel product platforms that offer the potential to target known, and well understood